Nrf2 Activation With CDDO-Methyl Promotes Beneficial and Deleterious Clinical Effects in Transgenic Mice With Sickle Cell Anemia

• Hauptverfasser: Chibueze A. Ihunnah (Verfasst von), Samit Ghosh (Verfasst von), Scott Hahn (Verfasst von), Adam C. Straub (Verfasst von), Solomon F. Ofori-Acquah (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Activation of Nrf2, a major transcription factor that drives the antioxidant defense system, is an emerging therapeutic strategy in Sickle Cell Disease (SCD). In this study, transgenic Sickle Cell Anemia mice (SS mice) treated with CDDO-Methyl (CDDO-Me), a potent Nrf2 activator, showed reduced progr...